Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BMRA | US
-0.03
-1.17%
Healthcare
Diagnostics & Research
31/08/2024
05/06/2026
2.12
2.32
2.32
2.08
Biomerica Inc. a biomedical technology company develops patents manufactures and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood urine nasal or fecal specimens from patients in the diagnosis of various diseases food intolerances and other medical complications; or to measure bacteria hormones antibodies antigens or other substances which may exist in the human body stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases food intolerances and various esoteric tests at the physicians' offices and over-the-counter drugstores and hospital/clinical laboratories. The company is also developing InFoods that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; Helicobacter pylori test that indicates if a patient is infected with the H. Pylori bacteria. In addition it develops products to indicate if a person has been infected by COVID-19. Biomerica Inc. was incorporated in 1971 and is headquartered in Irvine California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
42.6%1 month
51.3%3 months
53.0%6 months
52.8%-
-
1.07
0.13
0.09
-5.42
0.65
-
-6.42M
35.66M
35.66M
-
-75.71
-
5.50
-76.48
0.47
2.81
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.43
Range1M
0.43
Range3M
0.62
Rel. volume
0.75
Price X volume
32.25K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Neuronetics Inc | STIM | Diagnostics & Research | 1.29 | 39.09M | -11.64% | n/a | 323.03% |
| STAR EQUITY HOLDINGS INC | STRR | Diagnostics & Research | 11.3 | 36.40M | -3.00% | n/a | 26.85% |
| Aclarion Inc | ACON | Health Information Services | 3.57 | 35.86M | 1.13% | n/a | 47.32% |
| Precipio Inc | PRPO | Diagnostics & Research | 23.49 | 34.82M | 0.56% | n/a | 9.66% |
| MDxHealth SA | MDXH | Diagnostics & Research | 0.5659 | 26.76M | -5.68% | n/a | -643.01% |
| Cytosorbents Corporation | CTSO | Diagnostics & Research | 0.459 | 24.98M | -5.94% | n/a | 159.92% |
| bioAffinity Technologies Inc. | BIAF | Diagnostics & Research | 1.73 | 23.34M | -7.98% | n/a | 40.20% |
| BioTelemetry Inc | BEAT | Diagnostics & Research | 0.8389 | 22.28M | -7.36% | n/a | 0.00% |
| MYnd Analytics Inc | MYND | Diagnostics & Research | 0.4003 | 18.27M | -11.24% | n/a | 117.50% |
| XWEL | XWEL | Diagnostics & Research | 1.36 | 7.15M | -2.16% | n/a | 126.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Reading International Inc | RDI | Media - Diversified | 1.18 | 33.31M | 0.85% | n/a | 4054.78% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.02 | 14.90M | -4.67% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.428 | 8.27M | 2.39% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.32 | 3.37M | -13.16% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.3876 | 213.57K | -7.71% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.42 | 12.67 | Cheaper |
| Ent. to Revenue | 0.65 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 1.07 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 52.97 | 59.59 | Par |
| Debt to Equity | 0.13 | -14.36 | Expensive |
| Debt to Assets | 0.09 | 0.34 | Cheaper |
| Market Cap | 35.66M | 13.71B | Emerging |